Molecular nuclear imaging: The radiopharmaceuticals (Review)

被引:33
作者
Imam, SK [1 ]
机构
[1] Liverpool Hosp, Dept Nucl Med, Sydney, NSW 2170, Australia
关键词
molecular imaging; radiopharmaceuticals; FDG; FLT; annexin;
D O I
10.1089/cbr.2005.20.163
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Application of the nuclear approach for the detection of inherited diseases is an important goal for nuclear medicine and will likely result in an important breakthrough, which will, hopefully, lead to improved diagnoses of genetic defects and objective evaluations of the efficacy of therapeutic strategies. Although still largely in the research realm, molecular imaging is in the process of emerging as a vital component of the diagnosis of disease and monitoring of the therapy. The clinical research in nuclear medicine has made major advancements in the direction of molecular medicine and targeted therapy. In the past few years, exponential achievements have been accomplished in the development of molecular nuclear imaging agents, as described below.
引用
收藏
页码:163 / 172
页数:10
相关论文
共 51 条
[1]  
Barthel H, 2003, CANCER RES, V63, P3791
[2]   The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis [J].
Bastiaannet, E ;
Groen, H ;
Jager, PL ;
Cobben, DCP ;
van der Graaf, WTA ;
Vaalburg, W ;
Hoekstra, HJ .
CANCER TREATMENT REVIEWS, 2004, 30 (01) :83-101
[3]  
Belhocine T, 2002, CLIN CANCER RES, V8, P2766
[4]   In vivo detection and imaging of phosphatidylserine expression during programmed cell death [J].
Blankenberg, FG ;
Katsikis, PD ;
Tait, JF ;
Davis, RE ;
Naumovski, L ;
Ohtsuki, K ;
Kopiwoda, S ;
Abrams, MJ ;
Darkes, M ;
Robbins, RC ;
Maecker, HT ;
Strauss, HW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (11) :6349-6354
[5]  
BLASBERG R, 2002, MOL IMAGING, V1, P160
[6]   A multicenter trial with a somatostatin analog 99mTc depreotide in the evaluation of solitary pulmonary nodules [J].
Blum, J ;
Handmaker, H ;
Lister-James, J ;
Rinne, N .
CHEST, 2000, 117 (05) :1232-1238
[7]   Practical benefit of [I-123]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease [J].
Booij, J ;
Tissingh, G ;
Winogrodzka, A ;
Boer, GJ ;
Stoof, JC ;
Wolters, EC ;
vanRoyen, EA .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1997, 24 (01) :68-71
[8]  
Buck AK, 2003, J NUCL MED, V44, P1426
[9]  
CARSWELL CI, 2002, AM J CANC, V1, P341
[10]  
CHETANNEAU A, 2003, MED NUCL, V27, P265